May 23, 2017 3:40am
From Maureen Tacke, Idaho; Hi George, my colleagues and I enjoy the Fratsma Factor postings you send. Thank you for the work that you do instilling best practice across the nation. Each year at the PTT lot change, we redo the heparin response curve. We’ve done this to follow practices from years prior. We’ve noted in the CAP checklist that after the initial response curve, it is only necessary to compare the current lot with the new lot of PTT. We are considering changing practices, and wanted to hear your thoughts on the matter. CAP does not dictate the correlation coefficient range between lots. What would you recommend? 0.9 – 1.1? Smaller? Eventually, we’d like to change practice within our pharmacy so that they monitor patients via anti-Xa. But we are not quite to that point yet with our pharmaceutical colleagues. Thank you for your time.
May 11, 2017 7:16pm
The North American Society on Thrombosis and Hemostasis has announced the winners of the 2017 Research Fellowship Award. Click or tap here to see the lead banner of the NASTH web site with photos and biosketches of the winners. Congratulations!
May 4, 2017 9:26am
George recommends the April CAP Today article, Hemophilia Management, Tips on Monitoring Modified Replacement Therapies. The article, featuring Stefan Tiefenbacher, PhD, of Colorado Coagulation, and Rajiv K.
1 Comment
Apr 22, 2017 7:40am
An intriguing case from Heather DeVries, Indiana University Health. Hi George, I have an interesting (cold) case study for you. We recently tested a 44 yo female for lupus antibodies and she had textbook results--nothing equivocal about them. Her history includes a late-term pregnancy loss 12 years ago, and a recent diagnosis of lupus, so it seems that she could now be considered to have antiphospholipid antibody syndrome (APS). This is where the family history comes in.